Israeli-founded Canadian-based RetiSpec has developed the RS1, which uses hyperspectral retinal imaging and AI to examine the back of the eye. It can identify harmful amyloid proteins and other evidence that indicate Alzheimer’s Disease, even before the patient shows symptoms.
Retinal scanner for early Alzheimer’s test
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.